Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

46.99 -0.93 (-1.94%)
Streaming Delayed Price Updated: 2:29 PM EDT, Aug 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
78 79 Next >
3 Top ETFs to Buy for Passive Income in May
These ETFs provide investors with above-average income streams. 
Via The Motley Fool
Topics ETFs
A Closer Look at Bristol-Myers Squibb's Options Market Dynamics
 
Via Benzinga
How Is The Market Feeling About Bristol-Myers Squibb?
 
Via Benzinga
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages. 
Via Benzinga
Topics Stocks
Last Week's Worst-Performing Stocks: Are These 10 Large-Cap Stocks In Your Portfolio? (April 21-27, 2024)
10 worst performing large-cap stocks last week: LKQ, MSCI, TXT, EDU, BMY, MANH, RS, META, LUV, NUE. Analysts cut price targets for many. 
Via Benzinga
Why Bristol Myers Squibb Stock Is Sinking Today
Investors didn't like the biopharmaceutical company's updated guidance. 
Via The Motley Fool
A Closer Look at Bristol-Myers Squibb's Options Market Dynamics
 
Via Benzinga
Peeling Back The Layers: Exploring Bristol-Myers Squibb Through Analyst Insights
 
Via Benzinga
Stock Market Rebounds; Tesla, Microsoft, Google, Meta, Chipotle, GE In Focus: Weekly Review
Microsoft, Tesla, Google, GE and Chipotle were earnings winners. Meta was a notable loser. 
Via Investor's Business Daily
CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
From Bristol Myers Squibb
Via Business Wire
Investor Sentiment Improves Slightly, But Dow Tumbles Over 350 Points
 
Via Benzinga
Topics Stocks
Crude Oil Moves Higher; Bristol Myers Squibb Shares Fall After Q1 Results
 
Via Benzinga
Bristol Myers Squibb Swings To Quarterly Loss, After String Of Multi-Billion Acquisitions
Discover Bristol Myers Squibb's impressive first-quarter performance, with revenues exceeding expectations driven by key products like Eliquis and Reblozyl. Despite challenges, the company aims for... 
Via Benzinga
PLTR Stock: Palantir Beefs Up Healthcare AI Work Through Parexel Deal
Palantir stock is slipping on Thursday even as PLTR traders learn of a new contract between the data company and Parexel. 
Via InvestorPlace
Topics Artificial Intelligence
BMY Stock Earnings: Bristol-Myers Squibb Beats EPS, Beats Revenue for Q1 2024
BMY stock results show that Bristol-Myers Squibb beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
 
Via Benzinga
Bristol-Myers Squibb Layoffs 2024: What to Know About the Latest BMY Job Cuts
Bristol-Myers Squibb layoffs will see the company reduce its headcount by 6% as part of an effort to reduce expenses in 2024. 
Via InvestorPlace
Topics Workforce
Bristol Myers Squibb (BMY) Q1 2024 Earnings Call Transcript
BMY earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
Is Bristol Myers Squibb Stock a Millionaire Maker?
Bristol Myers Squibb faces some challenges, but there could be light at the end of the tunnel for long-term investors. 
Via The Motley Fool
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
The radiopharmaceuticals space could be worth up to $25 billion, according to one estimate. 
Via Investor's Business Daily
AstraZeneca, Sanofi Jump On First-Quarter Earnings; Bristol Myers Lags
AstraZeneca soundly topped analyst views while Sanofi narrowed its losses. Both stocks surged in early trade. 
Via Investor's Business Daily
Bristol Myers Squibb Reports First Quarter Financial Results for 2024
From Bristol Myers Squibb
Via Business Wire
Novartis Stock Gains On European Drugmaker's Q1 Earnings Surprise, Lifts Annual Outlook
Discover Novartis' Q1 EPS soars 17% to $1.80, surpassing estimates. Sales hit $11.83B, up 10%. Entresto sales surge 36%, Cosentyx up 25%. CEO Vas Narasimhan bullish on mid & long-term growth. 
Via Benzinga
US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says Analyst
The back-and-forth motion in the market continues, with the index futures pointing to a lower opening on Thursday. Meta Platforms, Inc.’s (NASDAQ:META) 
Via Benzinga
5 Crash-Proof Stocks to Buy Immediately
We may not be headed to a full-blown crisis, but savvy investors should protect their portfolios now with these crash-proof stocks. 
Via InvestorPlace
Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster
From Bristol Myers Squibb
Via Business Wire
3 High-Yielding Dividend Stocks That Are Trading at Dirt-Cheap Valuations
These stocks pay between 3.2% and 6.7% in dividends. 
Via The Motley Fool
These 3 Small-Cap Stocks Are Up 304% in 2024. Can They Run Higher?
Small-cap stocks have been the market laggards but these standouts showed how to beat even top-tier tech names at their own game. 
Via InvestorPlace
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
Corporate profit growth rose in Q3 2023 and is expected to continue in Q1. 
Via Benzinga
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies
Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings—the highest safety-rel 
Via Benzinga
< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
78 79 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.